EMPA-REG - The "diuretic hypothesis"

Journal of Diabetes and its Complications

Volumn 30, Issue 1, 2016, Pages 3-4

  McMurray, John ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; EMPAGLIFLOZIN; MINERALOCORTICOID ANTAGONIST; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

DEATH; EDITORIAL; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LUNG CONGESTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM RETENTION; WATER RETENTION; ANTAGONISTS AND INHIBITORS; ARRHYTHMIAS, CARDIAC; BIOLOGICAL MODEL; COMPLICATION; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; METABOLISM; RISK;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; BENZHYDRYL COMPOUNDS; CONTROLLED CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DIURETICS; GLUCOSIDES; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; MEMBRANE TRANSPORT MODULATORS; MODELS, BIOLOGICAL; RISK; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84952637177     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2015.10.012     Document Type: Editorial

References (16)

1. I.S. Anand, G.S. Kalra, R. Ferrari, P.L. Wahi, P.C. Harris, and P.A. Poole-Wilson Enalapril as initial and sole treatment in severe chronic heart failure with sodium retention International Journal of Cardiology 28 1990 341 346
2. Blood Pressure Lowering Treatment Trialists' Collaboration J. Sundström, H. Arima, M. Woodward, R. Jackson, and K. Karmali B. Neal Blood pressure-lowering treatment based on cardiovascular risk: A meta-analysis of individual patient data Lancet 384 2014 591 598
3. L.J. Boonman-de Winter, F.H. Rutten, M.J. Cramer, M.J. Landman, A.H. Liem, G.E. Rutten, and A.W. Hoes High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes Diabetologia 55 2012 2154 2162
4. B.R. Davis, L.B. Piller, J.A. Cutler, C. Furberg, K. Dunn, and S. Franklin Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group Role of diuretics in the prevention of heart failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Circulation 113 2006 2201 2210
5. E. Erdmann, B. Charbonnel, R.G. Wilcox, A.M. Skene, M. Massi-Benedetti, and J. Yates PROactive investigators Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: Data from the PROactive study (PROactive 08) Diabetes Care 30 2007 2773 2778
6. R.E. Gilbert, and H. Krum Heart failure in diabetes: Effects of anti-hyperglycaemic drug therapy Lancet 385 2015 2107 2117
7. M. Komajda, J.J. McMurray, H. Beck-Nielsen, R. Gomis, M. Hanefeld, and S.J. Pocock P.D. Home Heart failure events with rosiglitazone in type 2 diabetes: Data from the RECORD clinical trial European Heart Journal 31 2010 824 831
8. M. Mamdani, D.N. Juurlink, D.S. Lee, P.A. Rochon, A. Kopp, and G. Naglie T.A. Stukel Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study Lancet 363 2004 1751 1756
9. J.J. McMurray Clinical practice. Systolic heart failure The New England Journal of Medicine 362 2010 228 238
10. J.J. McMurray, H.C. Gerstein, R.R. Holman, and M.A. Pfeffer Heart failure: A cardiovascular outcome in diabetes that can no longer be ignored The Lancet Diabetes & Endocrinology 2 2014 843 851
11. M.A. Pfeffer Blood pressure in heart failure: A love-hate relationship Journal of the American College of Cardiology 49 2007 40 42
12. B.M. Scirica, E. Braunwald, I. Raz, M.A. Cavender, D.A. Morrow, and P. Jarolim D.L. Bhatt SAVOR-TIMI 53 Steering Committee and Investigators∗. Heart failure, saxagliptin, and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial Circulation 130 2014 1579 1588
13. M. Škrtić, and D.Z. Cherney Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy Current Opinion Nephrology and Hypertension 24 1 2015 96 103
14. SPRINT Research Group A randomized trial of intensive versus standard blood-pressure control The New England Journal of Medicine 2015 Nov 9 [Epub ahead of print]
15. F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, and H. Shi EMPHASIS-HF Study Group Eplerenone in patients with systolic heart failure and mild symptoms The New England Journal of Medicine 364 2011 11 21
16. B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, and S. Hantel EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes The New England Journal of Medicine 2015 Sep 17 [Epub ahead of print]